Role of MAPKs in platinum-induced neuronal apoptosis
Introduction
The type and severity of Chemotherapy-Induced Peripheral Neuropathy (CIPN) is generally related to the drug used, the duration of the administration and the cumulative dose. Even if the peripheral nervous system has a great capacity for regeneration after injury, CIPN is only partly reversible and, in the worst cases, damage is irreversible (Cavaletti et al., 2001). Platinum derivatives are cytotoxic on tumoral cells by forming platinum-DNA adducts, thus leading the tumor cells to programmed cell death. A similar mechanism has been suggested for the toxicity of cisplatin on Dorsal Root Ganglia (DRG) neurons, the main target of cisplatin-induced peripheral neurotoxicity (Cavaletti et al., 2001). In vitro and in vivo studies have suggested that cisplatin-induced apoptosis in DRG neurons is related to changes in the expression of cell cycle proteins (Gill and Windebank, 1998, Fisher et al., 2001, McDonald et al., 2005). These changes have been interpreted as an abortive attempt to re-enter the cell cycle by post-mitotic cells, which the neurons are (Gill and Windebank, 1998). At present, little is known about the many other possible molecular mechanisms that may be relevant to the onset of platinum derivative apoptosis in DRG neurons.
Recently, some studies have reported the involvement of members of the Mitogen-Activated Protein Kinases (MAPK) family in different models of peripheral nerve damage (Purves et al., 2001, Colucci-D’Amato et al., 2003, Gozdz et al., 2003, Myers et al., 2003, Price et al., 2004) making this family of serine-threonine kinases, which includes extracellular signaling-regulated kinase (ERK1/2, also termed p44/42), NH2-terminal c-Jun Kinase/Stress Activated Protein Kinase (JNK/Sapk), and p38, a good candidate for a role in DRG neuron apoptosis after exposure to platinum derivatives (Cavaletti et al., 2007).
MAPKs control a wide variety of cellular functions such as the proliferation, differentiation and regulation of apoptosis (Lewis et al., 1998). ERKs1/2 are generally activated by proliferation or differentiation stimuli, while JNK/Sapk and p38 mediate the cellular response to stress signals, even if the role of MAPK members is not so narrowly defined. ERKs are highly expressed in mature neurons and their activation has been observed in many forms of synaptic plasticity, in learning and memory (Thomas and Huganir, 2004) and in neurite outgrowth (Williams et al., 2000), but also in neurodegeneration (Colucci-D’Amato et al., 2003), apoptosis (Choi et al., 2004, Stoica et al., 2005, Oh et al., 2006) and in oxidative stress that has resulted in neuronal damage (Purves et al., 2001). ERK activation has been observed after cisplatin treatment in cortical neurons and has been interpreted as a protective response by neurons to injury (Gozdz et al., 2003). Therefore, ERK activation alone is not predictive of the cellular response, since they may be involved either in neuronal survival and differentiation or even in cell death.
There are also controversial observations regarding JNK/Sapk which is usually activated by stress signals and which mediates apoptosis (Nicolini et al., 2003, Donzelli et al., 2004, Oh et al., 2006). Recently, however, this protein has been related to neuronal differentiation and neurite outgrowth (Giasson et al., 1999, Coffey et al., 2000). JNK/Sapk mediates also DNA repair and cellular viability after chemotherapy treatment (Potapova et al., 1997). In some neuropathies such as in experimental diabetes, JNK/Sapk is activated, although there is no evidence of cellular death. Based on these results, some authors have hypothesized a protective role for this protein (Middlemas et al., 2003).
On the contrary, almost all reports agree in indicating p38 as a protein that mediates stress signals in cells (Raingeaud et al., 1995, Ozaki et al., 1999, Nakahara et al., 1999, Hao et al., 2006). In diabetic neuropathy, p38 activation is closely related to a reduction in nerve conduction velocity (Price et al., 2004) and mediates oxidative stress damage (Purves et al., 2001). However, it has been reported that PC12 differentiation occurs in a p38 activity-dependent manner (Takeda and Ichijo, 2002).
In the present study, we focused our attention on the MAPK role in sensory neuron damage induced by cisplatin (CDDP) and oxaliplatin (OHP), two antineoplastic agents widely used in the therapy of several solid tumors (Misset, 1998).
Section snippets
Materials and methods
All the procedures on animals were carried out under anesthesia in accordance with the European Communities Council Directive 86/609/EEC.
Results
In order to determine the drug concentrations to use in the present study we tested different OHP and CDDP doses at different time points (2 → 24 h). On the basis of these results, for our experiments, we chose the 100 μM OHP and 30 μM CDDP doses, both of which cause a neuronal death of about 60–70%. The drug concentrations we used in the present study are representative of the plasmatic concentrations of OHP and CDDP in patients (Grolleau et al., 2001, Quasthoff and Hartung, 2002). For both drugs
Discussion
In the present study, we have demonstrated that the two anticancer platinum derivates, CDDP and OHP, induce apoptosis in DRG neurons, by modulating the proteins of the Bcl-2 family which regulate the survival or death of the cells (Davies, 1995). Moreover, our work try to shed light on the molecular pathway, still poorly understood, exploited by anticancer drugs to induce neuronal neurotoxicity. We have demonstrated that MAPKs are involved in apoptosis induced by OHP and CDDP in DRG sensory
Acknowledgement
We are grateful to Dr. E. Genton for language assistance.
References (54)
- et al.
Pharmacologic inhibitors of MKK1 and MKK2
Methods Enzymol
(2001) - et al.
Role of MAPK in ceramide-induced cell death in primary cultured astrocytes from mouse embryonic brain
Neurotoxicology
(2004) - et al.
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1
FEBS Lett
(1995) The Bcl-2 family of proteins, and the regulation of neuronal survival
TINS
(1995)- et al.
Role of N-methyl-d-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin
J Biol Chem
(2003) - et al.
Extracellular-signal-regulated kinase signalling in neurons
Curr Opin Neurobiol
(1999) - et al.
Induction of apoptosis by the Ste20-like kinase SLK, a germinal center kinase that activates apoptosis signal-regulating kinase and p38
J Biol Chem
(2006) - et al.
Regulation of Bax translocation through phosphorylation at Ser-70 of Bcl-2 by MAP kinase in NO-induced neuronal apoptosis
Mol Cell Neurosci
(2003) - et al.
Signal transduction through MAP kinase cascades
Adv Cancer Res
(1998) - et al.
Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity
Neurobiol Dis
(2005)
Inhibition of p38 MAP kinase activity enhances axonal regeneration
Exp Neurol
Effects of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells
Neurochem Int
Role of MAPK in ceramide-induced cell death in primary cultured astrocytes from mouse embryonic brain
Neurotoxicology
Activation of stress-activated Protein Kinase/c-Jun NH2-terminal Kinase and p38 Kinase in calphostin C-induced apoptosis requires caspase-3-like proteases but is dispensable for cell death
J Biol Chem
The jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin
J Biol Chem
Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine
J Biol Chem
Adult mesenchymal stem cells rescue dorsal root ganglia neurons from dying
Brain Res
Ceramide induces neuronal apoptosis through mitogen-activated protein kinases and causes release of multiple mitochondrial proteins
Mol Cell Neurosci
Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin
Bioorg Med Chem
MEKK1 controls neurite regrowth after experimental injury by balancing ERK1/2 and JNK2 signaling
Mol Cell Neurosci
Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta
J Biol Chem
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Proc Natl Acad Sci USA
Emerging role of mitogen-activated protein kinases in peripheral neuropathies
Peripher Nerv Syst
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat
Eur J Cancer
ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning
Learn Mem
Dual roles for c-Jun N-terminal kinases in development and stress responses in cerebellar granule neurons
J Neurosci
Chronic activation of ERK and neurodegenerative diseases
Bioassays
Cited by (90)
Time dependent cisplatin dosing differences on hypoalgesia focusing on oxidative stress
2023, European Journal of PharmacologyNeurologic complications of oncologic therapy
2022, Handbook of Neuro-Oncology NeuroimagingClinical and biochemical markers in CIPN: A reappraisal
2021, Revue NeurologiqueCitation Excerpt :In addition, the oxaliplatin metabolite oxalate is responsible for extracellular Ca2+ chelation, which has been proposed to contribute to an increase in Na+ conductance and a reduction of membrane potential [37]. Changes in intracellular Ca2+ concentration have also been observed to induce MAPK-related apoptosis in DRG neurons [38]. Cisplatin apparently induces an up-regulation of the N-type voltage-gated Ca2+ channels (CaV2.2), albeit its contribution to the clinical presentation is still unclear [39,40].